38 KB127 KB24 KB192920262008Mlakar, Urošštevilka:15 straniletnik:77str. I-31-I-35ISSN:1318-0347COBISSID:24127449URN:URN:NBN:SI:doc-TJKE5VMNslSlovensko zdravniško društvoZdravniški vestnikAdultBrez bolezni, preživetjeDisease-Free SurvivalDrug TherapyhematologijakemoterapijaLeukemia, Myelocytic, AcutelevkemijaLevkemija mielocitna, akutnaOdrasliPreživetje, analizaSurvival AnalysistherapyzdravljenjeZdravljenje akutne mieloične levkemije odraslih - 5-letne izkušnje v UKC Ljubljana| Treatment of acute myeloid leukemia of adults - 5-years experience at University clinical center Ljubljana|Background Over the last 30 years there has been significant improvement in survival of patients with acute myeloid leukemia (AML) under 60 years of age who have entered clinical trials. In older patients who have been treated withintensive chemotherapy over the same period, there was little evidence of any improvement in survival. Only minority of older patients entered trials and presumably they were in best clinical condition that is why they formed a highly selected group. Therefore analysis of unselected older patients treatedin a single center has special value. We analyzed the outcome of treatment of adult patients with AML at the University Medical Center of Ljubljana. Results A retrospective study on acute myeloid leukemia (AML) patients was carried out on 235 patients treated during 5 year period. 14 patients with acute promyelocytic leukemia (APL) received tretinoin and athracycline based chemotherapy. Three of these patients died during inductionperiod and others are still in the first remission. In the group of non-APL patients 84 patients under age of 60 and 81 patients above 59 years ofage received intensive chemotherapy. Non-intensive treatment was offered to 56 patients over the age of 59. Intensive chemotherapy with DAT/DA regimens was used for treatment of younger patients. Beside DAT/DA regimen 36% percent of older patients on intensive treatment received ICE regimen. For younger patients the induction death rate and complete remission (CR) rates were 10% and 70% respectively. Among those who achieved CR, the disease free survival (DFS) after 4 years was 56%. Overall survival after the same period was 53%. For older patients on intensive chemotherapy induction death and CR rates were27% and 46%. Overall survival and DFS after three years were 12%. There was no difference in treatment efficacy between DAT/DA and ICE regimen. (Abstract truncated at 2000 characters)TEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo